Healthcare Services company Vimta Labs announced Q2FY26 results Q2FY26 Financial Highlights: Total Income for Q2FY26 was at Rs 1,045 million EBITDA for Q2FY26 was Rs 369 million; EBITDA margin was at 35.3% PBT for Q2FY26 was at Rs 263 million Q2FY26 PAT was at Rs 199 million; PAT margin was at 19.1% Basic EPS in Q2FY26 was Rs 4.5 H1FY26 Financial Highlights: Total Income for H1FY26 was at Rs 2,038 million EBITDA for H1FY26 was Rs 723 million; EBITDA margin was at 35.5% PBT for H1FY26 was at Rs 515 million H1FY26 PAT was at Rs 388 million; PAT margin was at 19.0% Basic EPS in H1FY26 was Rs 8.7 Harita Vasireddi, Managing Director, Vimta Labs, said: "I am delighted to share that Vimta Labs had a successful quarter with highest ever revenue reported i.e. ~Rs 104 crore. This growth was a result of our Pharmaceutical research and testing services and Food testing services performing well, while experiencing stable performance from other services provided by us. We would like to mention that our company had a successful WHO audit for Clinical Research during the quarter, reflecting our commitment to maintain the highest global standards of quality and compliance. With a focus on maintaining excellence in quality, innovation, and competence, we continue to strengthen our capabilities and deliver sustainable value to all stakeholders.” Result PDF